A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling

Aim Use of immunomodulating therapeutics for immune‐mediated inflammatory diseases may cause disease‐drug‐drug interactions (DDDIs) by reversing inflammation‐driven alterations in the metabolic capacity of cytochrome P450 enzymes. European Medicine Agency (EMA) and US Food and Drug Administration (F...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of clinical pharmacology 2022-10, Vol.88 (10), p.4387-4402
Hauptverfasser:	Jong, Laura M., Klomp, Sylvia D., Treijtel, Nicoline, Rissmann, Robert, Swen, Jesse J., Manson, Martijn L.
Format:	Artikel
Sprache:	eng
Schlagworte:	cytochrome P450 enzymes (CYP) cytokines disease‐drug‐drug interactions drug labelling drug‐drug interactions EMA FDA immunomodulation inflammation monoclonal antibody phenoconversion SPC therapeutic proteins tyrosine kinase inhibitor USPI
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!